Pluristem
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase I… Read more
Pluristem (PSTI) - Net Assets
Latest net assets as of March 2022: ILA40.14 Million ILA
Based on the latest financial reports, Pluristem (PSTI) has net assets worth ILA40.14 Million ILA as of March 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA79.13 Million) and total liabilities (ILA38.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA40.14 Million |
| % of Total Assets | 50.73% |
| Annual Growth Rate | -1.18% |
| 5-Year Change | 88.92% |
| 10-Year Change | N/A |
| Growth Volatility | 61.24 |
Pluristem - Net Assets Trend (2014–2021)
This chart illustrates how Pluristem's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pluristem (2014–2021)
The table below shows the annual net assets of Pluristem from 2014 to 2021.
| Year | Net Assets | Change |
|---|---|---|
| 2021-06-30 | ILA57.15 Million | +1.87% |
| 2020-06-30 | ILA56.10 Million | +157.10% |
| 2019-06-30 | ILA21.82 Million | -23.45% |
| 2018-06-30 | ILA28.51 Million | -5.77% |
| 2017-06-30 | ILA30.25 Million | -20.72% |
| 2016-06-30 | ILA38.16 Million | -34.38% |
| 2015-06-30 | ILA58.14 Million | -6.41% |
| 2014-06-30 | ILA62.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pluristem's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21618700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2021)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ILA387.17 Million | 677.45% |
| Total Equity | ILA57.15 Million | 100.00% |
Pluristem Competitors by Market Cap
The table below lists competitors of Pluristem ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Grade Upon Technology Corp
TWO:6739
|
$313.64K |
|
WEIR GROUP
BE:42W
|
$313.87K |
|
Grayscale Digital Large Cap Fund Ll
OTCQX:GDLC
|
$313.99K |
|
Constellation Acquisition Corp I
OTCQB:CSTUF
|
$314.12K |
|
TRAFALGA PPTY GR.LS-001
F:8Q5
|
$313.51K |
|
Michichi Capital Corp.
V:MCCP-P
|
$313.32K |
|
Lombard et Medot SA
PA:MLCAC
|
$313.24K |
|
Infinico Metals Corp.
V:INFM
|
$313.22K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pluristem's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2020 to 2021, total equity changed from 56,101,000 to 57,151,000, a change of 1,050,000 (1.9%).
- Net loss of 49,865,000 reduced equity.
- New share issuances of 36,589,000 increased equity.
- Other factors increased equity by 14,326,000.
Equity Change Factors (2020 to 2021)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-49.87 Million | -87.25% |
| Share Issuances | ILA36.59 Million | +64.02% |
| Other Changes | ILA14.33 Million | +25.07% |
| Total Change | ILA- | 1.87% |
Book Value vs Market Value Analysis
This analysis compares Pluristem's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 570.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 326.86x to 570.37x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-06-30 | ILA3.12 | ILA1020.00 | x |
| 2018-06-30 | ILA2.51 | ILA1020.00 | x |
| 2019-06-30 | ILA1.45 | ILA1020.00 | x |
| 2020-06-30 | ILA2.20 | ILA1020.00 | x |
| 2021-06-30 | ILA1.79 | ILA1020.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pluristem utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -87.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.64x
- Recent ROE (-87.25%) is below the historical average (-78.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -43.35% | -7106.07% | 0.01x | 1.19x | ILA-33.14 Million |
| 2015 | -42.44% | -6511.08% | 0.01x | 1.17x | ILA-30.49 Million |
| 2016 | -60.92% | -816.51% | 0.06x | 1.20x | ILA-27.06 Million |
| 2017 | -91.94% | 0.00% | 0.00x | 1.24x | ILA-30.84 Million |
| 2018 | -91.65% | -52252.00% | 0.00x | 1.37x | ILA-28.98 Million |
| 2019 | -161.80% | -65383.33% | 0.00x | 1.43x | ILA-37.49 Million |
| 2020 | -51.96% | -126747.83% | 0.00x | 1.17x | ILA-34.76 Million |
| 2021 | -87.25% | 0.00% | 0.00x | 1.64x | ILA-55.58 Million |
Industry Comparison
This section compares Pluristem's net assets metrics with peer companies in the Biotechnology & Medical Research industry.
Industry Context
- Industry: Biotechnology & Medical Research
- Average net assets among peers: $17,638,000
- Average return on equity (ROE) among peers: 0.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pluristem (PSTI) | ILA40.14 Million | -43.35% | 0.97x | $313.59K |
| Hadasit Bio (HDST) | $17.64 Million | 0.00% | 0.20x | $37.28K |